Abstract 3134
Background
Although neuroendocrine tumours (NET) constitute a very heterogeneous group, most of them express somatostatin receptors that enable treatment with somatostatin analogues, which proved to be effective both as bio- or radiopeptide therapy. However, little is now about combining these two treatment modalities. The aim of our prospective study was to evaluate the results of radiolabeled somatostatin analogues (PRRT) with or without "cold" somatostatin analogues (SA) as consolidation treatment.
Methods
Patients with well-differentiated NET treated with PRRT (4 to 5 cycles repeated every 6 to 12 weeks) were included in the study. After the last cycle of PRRT response to radiopeptide treatment was evaluated with the scintigraphic, radiological and biochemical examination. Thereafter patients were randomly assigned either to treatment with SA or observation group (2:1 randomization). Initiation of the next line of therapy was left to the discretion of treating physician. Patients were followed-up at 4-12 months intervals with radiological examinations (CT or MRI) and receptors scintigraphy. The median time to progression was measured from the start of PRRT treatment till the day of disease progression confirmed in the radiological or scintigraphic examination.
Results
125 patients (79 in SA and 46 in the observation group) were included in the study. 81 patients were randomly assigned to somatostatin analogs and 44 to the observation group. The median follow-up the calculated from the start of PRRT was 54 months for the whole group of patients. During that time 85 (68%) progressed. There was a trend to longer progression-free survival in SSA group (47 vs 44 months), however, the difference was statistically insignificant. During observation period 32 patients died and there was no difference in time to death between both groups. In 9 patients after radiopeptide therapy chemotherapy was given. Chemotherapy was well tolerated and there were no late serious side effects.
Conclusions
Preliminary results suggest that consolidation treatment with SA did not improve the results of PRRT. However, a larger number of patients and longer follow-up is necessary.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D. Handkiewicz Junak: Travel / Accommodation / Expenses: Ipsen Novartis Genzyme-Sanofi. B. Jurecka-Lubieniecka: Travel / Accommodation / Expenses: Ipsen Novartis. B. Jarzab: Travel / Accommodation / Expenses: Ipsen Novartis Genzyme-Sanofi. All other authors have declared no conflicts of interest.
Resources from the same session
3248 - Second-line palliative systemic treatment for synchronous metastatic esophagogastric cancer: a population-based study
Presenter: Willemieke Dijksterhuis
Session: Poster Display session 2
Resources:
Abstract
4331 - STING Agonist, ADU-S100, Yields Potent Antitumor Activity and Therapeutically Favorable Immune Profile in an Esophageal Adenocarcinoma Model
Presenter: Ali Zaidi
Session: Poster Display session 2
Resources:
Abstract
1770 - Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
Presenter: Willemieke Dijksterhuis
Session: Poster Display session 2
Resources:
Abstract
3755 - A new docetaxel (DOC)-based triplet regimen does not improve the outcome of metastatic (M) or locally advanced (LA) gastric cancer (GC) as compared with an epirubicin (EPI) standard triplet regimen: a GISCAD trial.
Presenter: Roberto Labianca
Session: Poster Display session 2
Resources:
Abstract
2439 - The analysis of T cell subsets and clinical efficacy of immune checkpoint blockades in patients with advanced gastric cancer using multiplex immunohistochemistry
Presenter: Tae-yong Kim
Session: Poster Display session 2
Resources:
Abstract
2211 - First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma.
Presenter: Yelena Janjigian
Session: Poster Display session 2
Resources:
Abstract
3046 - Monitoring patient-specific mutation in ctDNA and CTC for tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric cancer (NCT03425058)
Presenter: Tao Fu
Session: Poster Display session 2
Resources:
Abstract
4628 - Gastric cancer screening in BRCA 2 gene mutation carriers: should it be recommended?
Presenter: Inês Oliveira
Session: Poster Display session 2
Resources:
Abstract
2127 - Interim analysis of an observational/translational study for nivolumab treatment in advanced gastric cancer: JACCRO GC-08 (DELIVER trial)
Presenter: Yu Sunakawa
Session: Poster Display session 2
Resources:
Abstract
2264 - Prediction of S-1 adjuvant chemotherapy efficacy in Stage II/III gastric cancer treatment based on comprehensive gene expression analysis
Presenter: Masanori Terashima
Session: Poster Display session 2
Resources:
Abstract